Evidence map›Paper›PMID 29710086›Full record

ArticleJAMA psychiatry2018

Physician Prescribing of Opioids to Patients at Increased Risk of Overdose From Benzodiazepine Use in the United States.

Joseph A Ladapo, Marc R Larochelle, Alexander Chen, Melissa M Villalon, Stefanie Vassar, David Y C Huang, John N Mafi

Open access · bronzeAbstract read
In one paragraph

Article in JAMA psychiatry, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
7.6field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 37 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Opioid Management: Initiating, Monitoring, and Tapering.Physical medicine and rehabilitation clinics of North America · 2020
    Review
  11. Article
  12. Article
  13. Coprescribing of Benzodiazepines and Opioids in Older Adults: Rates, Correlates, and National Trends.The journals of gerontology. Series A, Biological sciences and medical sciences · 2019
    Article
  14. Article
  15. Article
  16. Article
  17. Benzodiazepine Use and Misuse Among Adults in the United States.Psychiatric services (Washington, D.C.) · 2019
    Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Joseph A LadapoDivision of General Internal Medicine and Health Services Research, David Geffen School of Medicine at University of California, Los Angeles.
Marc R LarochelleClinical Addiction Research and Education Unit, Section of General Internal Medicine, Department of Medicine, Boston Medical Center, Boston, Massachusetts.
Alexander ChenDivision of General Internal Medicine and Health Services Research, David Geffen School of Medicine at University of California, Los Angeles.
Melissa M VillalonDivision of General Internal Medicine and Health Services Research, David Geffen School of Medicine at University of California, Los Angeles.
Stefanie VassarDivision of General Internal Medicine and Health Services Research, David Geffen School of Medicine at University of California, Los Angeles.
David Y C HuangDivision of General Internal Medicine and Health Services Research, David Geffen School of Medicine at University of California, Los Angeles.
John N MafiDivision of General Internal Medicine and Health Services Research, David Geffen School of Medicine at University of California, Los Angeles.
University of California, Los Angeles · USBoston University · USRAND Corporation · US

Funding

UCLA Clinical Translational Science InstituteUL1TR001881 · NCATS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ARLEEN F. BROWN, ARASH NAEIM · 2016 to 2026
$118.1M
The Effect of Nanoparticle Encapsulated Resveratrol on Treatment of PeriodontitisKL2TR001882 · NCATS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Elizabeta Nemeth · 2016 to 2026
$13.1M
Financial incentive strategies for weight loss in obese patients living in socioeconomically disadvantaged neighborhoodsR01MD011544 · NIMHD · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI JAY, MELANIE, WALI, SOMA · 2016 to 2020
$3.5M
Improving urine drug test utility to mitigate prescription opioid riskK23DA042168 · NIDA · BOSTON MEDICAL CENTER · PI LAROCHELLE, MARC · 2017 to 2021
$956k
Patient-centered approaches to diagnosing coronary heart diseaseK23HL116787 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI LADAPO, JOSEPH ABIODUN · 2013 to 2017
$790k
NCATS NIH HHS KL2 TR001882NCATS NIH HHS UL1 TR001881NHLBI NIH HHS K23 HL116787NIDA NIH HHS K23 DA042168NIMHD NIH HHS R01 MD011544
6 · The paper itself

Abstract

Importance: Recent increases in US opioid-related deaths underscore the need to understand drivers of fatal overdose. The initial prescription of opioids represents a critical juncture because it increases the risk of future opioid use disorder and is preventable. Objective: To examine new opioid prescribing patterns in US patients at increased risk of overdose from benzodiazepine use. Design, Setting, and Participants: This study used publicly available data from the National Ambulatory Medical Care Survey and National Hospital Ambulatory Medical Care Survey from January 1, 2005, through December 31, 2015, to identify adults 20 years or older receiving new opioid prescriptions and concurrently using a benzodiazepine. Main Outcomes and Measures: Population-based rates of new opioid prescriptions stratified by use of benzodiazepines. Results: This study analyzed 13 146 visits, representing 214 million visits nationally, with a new opioid prescription. Rates of new opioid prescriptions among adults using a benzodiazepine increased from 189 to 351 per 1000 persons between 2005 and 2010 (rate difference, 162; 95% CI, 29-295; P = .02) and decreased to 172 per 1000 persons by 2015 (rate difference, -179; 95% CI, -310 to -48; P = .008). New opioid prescriptions in the general population not using benzodiazepines increased nonsignificantly from 78 to 93 per 1000 US persons between 2005 and 2010 (rate difference, 15; 95% CI, -3 to 33; P = .10) and decreased nonsignificantly to 79 per 1000 persons by 2015 (rate difference, -14; 95% CI, -38 to 11; P = .28). The likelihood of receiving a new opioid prescription during an ambulatory visit remained higher for patients concurrently using benzodiazepines compared with the general population after adjusting for demographic characteristics, comorbidities, and diagnoses associated with pain (adjusted relative risk, 1.83; 95% CI, 1.56-2.15; P < .001). Naloxone was coprescribed in less than 1% of visits when a patient concurrently used a benzodiazepine. Conclusions and Relevance: In 2010, new opioid prescriptions for US adults stopped increasing and began to decrease among higher-risk patients who used benzodiazepines. These patterns suggest that the recent increase in opioid-related deaths may be associated with factors other than physicians writing new opioid prescriptions. Nevertheless, prescribing among higher-risk patients still occurred at rates higher than rates in the general population, representing an important opportunity to improve quality of care for patients experiencing pain.

Indexed as

AdultAgedAnalgesics, OpioidBenzodiazepinesDrug OverdoseFemaleHealth Care SurveysHumansMaleMiddle AgedPractice Patterns, Physicians'RiskUnited StatesYoung AdultAnalgesics, OpioidBenzodiazepines

Identifiers

PMID29710086
PMCPMC6137520
OpenAlexW2797958228

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.